CasNo.442-52-4,Clemizole,(442-52-4) Suppliers

100 Gram	FOB Price: USD 1.0000

Min.Order :100 Gram
Purity: 98%
Payment Terms : L/C

Keywords

Clemizole Clemizole 442-52-4

Quick Details

Appearance:White crystal
Application:CAS：442-52-4； PXD101;N-HYDROXY-3-[3-[(PHENYLAMINO)SULFONYL]PHENYL]-2-PROPENAMIDE;N-HYDROXY-3-(3-PHENYLSULFAMOYLPHENYL)ACRYLAMIDE;Belinostat;Belinostat(PXD101);2-PropenaMide, N-hydroxy-3-[3-[(phenyl
PackAge:100g,500g,1kg,25kg
ProductionCapacity:1000|Gram|Month
Storage:Dry seal
Transportation:shipping

Superiority:

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.
IC50 Value: 8 mM (NS4B) [1]
Target: H1 receptor; Anti-HCV
in vitro: Although significant, clemizole's antiviral effect is moderate (50% effective concentration of 8 microM against an HCV genotype 2a clone). Combinations of clemizole with either interferon, ribavirin, or the nucleoside (NM283) and nonnucleoside (HCV796) HCV polymerase inhibitors were additive [1]. The differences in the rodent and human pathways for clemizole metabolism were of importance, because the predominant human metabolite was found to have synergistic anti-HCV activity [2].
in vivo: Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine [3].
Clinical trial: Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (CLEAN-1). NCT00945880. Phase 1

Details:

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.
IC50 Value: 8 mM (NS4B) [1]
Target: H1 receptor; Anti-HCV
in vitro: Although significant, clemizole's antiviral effect is moderate (50% effective concentration of 8 microM against an HCV genotype 2a clone). Combinations of clemizole with either interferon, ribavirin, or the nucleoside (NM283) and nonnucleoside (HCV796) HCV polymerase inhibitors were additive [1]. The differences in the rodent and human pathways for clemizole metabolism were of importance, because the predominant human metabolite was found to have synergistic anti-HCV activity [2].
in vivo: Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine [3].
Clinical trial: Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (CLEAN-1). NCT00945880. Phase 1